FDA clears first at-home brain device for depression

FDA approves first brain stimulation device for home depression treatment. Flow Neuroscience's FL-100 headset uses electrical ...
Clinical Advisor

FDA Clears At-Home Neuromodulation Device for Major Depressive Disorder

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.
MedPage Today on MSN

FDA approves at-home device for treatment-resistant depression

Prescription neuromodulation can be administered outside the clinic with physician oversig ...
MassDevice

Neurolief gets FDA approval for at-home neuromod that treats depression

Neurolief announced today that the FDA granted approval for its Proliv Rx at-home neuromodulation therapy for treating ...
Investor's Business Daily on MSN

Psychedelics-tied GH skyrockets on FDA go-ahead for depression drug

Biotech stock GH Research catapulted Monday after the FDA gave it the go-ahead to resume testing its depression drug.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA i…

NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in ...
abc7NY

FDA approves first postpartum depression pill in the US

The US Food and Drug Administration has approved the medication zuranolone for the treatment of postpartum depression - making it the first FDA-approved oral pill in the United States specifically for ...
abc7NY

FDA approves first-ever drug to treat postpartum depression

SAN FRANCISCO, California -- For the first time, the FDA has approved a medication specifically to treat new mothers who suffer from postpartum depression. The drug is called Brexanolone and will be ...
NJBIZ

FDA approves J&J’s Caplyta as add-on depression drug

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...